Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-04-05
2005-04-05
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S085100
Reexamination Certificate
active
06875738
ABSTRACT:
The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment of multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.
REFERENCES:
patent: 5350836 (1994-09-01), Kopchick et al.
patent: WO 9640772 (1996-12-01), None
patent: WO 9728258 (1997-08-01), None
patent: WO 9804698 (1998-02-01), None
patent: WO 9809642 (1998-03-01), None
patent: WO 9851705 (1998-11-01), None
Crump, M., P. et al., “Solution structure and basis for functional activity of stromal cell-derived factor-1: dissociation of CXCR4 activation from binding and inhibition of HIV-1”,Embo Journal, vol. 16, No. 23, 1997, pp. 6996-7007, XP-002915918.
Gupta et al., “Chemokine receptors in human endothelial cells”,J. Biol. Chem., vol. 273, No. 7, Feb. 1998, pp. 4282-4287, XP-002115362.
Dhib-Jalbut, S. et al., “Comparative effects of interferon—consensus 1, interferon -alpha 2a, and interferon -beta 1b on HLA expression and lymphoproliferation: a preclinical model for treatment of multiple sclerosis”,Journal of Interferon and Cytokine Research, vol. 16, No. 3, Mar. 1, 1996, pp. 195-200, XP-002081554.
Cwirla, S., E. et al., “Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine”,Science, vol. 276, Jun. 13, 1997, pp. 1696-1699, XP-002067303.
“Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomize, double-blind placebo-controlled trail”,Neurology, vol. 43, No. 4, Apr. 1, 1993, pp. 655-661, XP-000578355.
Nagasawa et al., “Defects of b-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1”,Nature, vol. 382, 1996, pp. 635-638, XP-002115695.
Loetscher et al., “N-terminal peptides of stromal cell-derived factor with CXC chemokine receptor 4 agonist and antagonist activities”,J. Biol. Chem., vol. 273, No. 35, Aug. 28, 1998, pp. 22279-22283, XP-002115696.
Clark-Lewis Ian
Duronio Vincent
Gong Jiang-Hong
Salari Hassan
Kemmerer Elizabeth C.
The University of British Columbia of Industry Liaison Office
Townsend and Townsend / and Crew LLP
LandOfFree
Therapeutic chemokine receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic chemokine receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic chemokine receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3406512